Leerink Partnrs Has Bearish Outlook for TNDM FY2028 Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Equities researchers at Leerink Partnrs lowered their FY2028 earnings estimates for shares of Tandem Diabetes Care in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will post earnings per share of $0.00 for the year, down from their previous forecast of $0.01. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.73) per share.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. During the same quarter last year, the business earned ($0.38) earnings per share. Tandem Diabetes Care’s revenue was up 31.4% compared to the same quarter last year.

A number of other equities research analysts have also recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Tandem Diabetes Care in a research note on Friday, October 4th. They set a “neutral” rating and a $46.00 price objective on the stock. Wells Fargo & Company upped their price target on shares of Tandem Diabetes Care from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group lowered their price objective on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Barclays upped their target price on Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Finally, Canaccord Genuity Group started coverage on Tandem Diabetes Care in a research note on Thursday, August 8th. They set a “buy” rating and a $57.00 price target for the company. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, Tandem Diabetes Care currently has an average rating of “Moderate Buy” and an average target price of $54.25.

Tandem Diabetes Care Stock Up 3.9 %

Shares of Tandem Diabetes Care stock opened at $31.22 on Tuesday. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care has a 1-year low of $18.45 and a 1-year high of $53.69. The business’s fifty day moving average price is $35.65 and its two-hundred day moving average price is $41.04. The company has a market capitalization of $2.05 billion, a P/E ratio of -15.56 and a beta of 1.36.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fred Alger Management LLC boosted its stake in shares of Tandem Diabetes Care by 45.2% during the 2nd quarter. Fred Alger Management LLC now owns 2,174,107 shares of the medical device company’s stock valued at $87,595,000 after buying an additional 677,036 shares during the period. Victory Capital Management Inc. boosted its position in Tandem Diabetes Care by 2,836.2% during the second quarter. Victory Capital Management Inc. now owns 403,370 shares of the medical device company’s stock valued at $16,252,000 after purchasing an additional 389,632 shares during the last quarter. Bellevue Group AG boosted its position in Tandem Diabetes Care by 19.9% during the third quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company’s stock valued at $78,496,000 after purchasing an additional 307,624 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Tandem Diabetes Care in the third quarter valued at about $10,208,000. Finally, First Light Asset Management LLC increased its position in Tandem Diabetes Care by 49.1% in the 2nd quarter. First Light Asset Management LLC now owns 708,482 shares of the medical device company’s stock worth $28,545,000 after purchasing an additional 233,405 shares during the last quarter.

Insider Activity at Tandem Diabetes Care

In other news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the transaction, the director now owns 195,190 shares in the company, valued at $5,855,700. This represents a 4.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.20% of the stock is owned by insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.